Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deglycyrrhizinated licorice (DGL) is a processed herbal extract derived from the root of *Glycyrrhiza glabra*. The refining process specifically removes glycyrrhizin, a constituent associated with mineralocorticoid-like side effects such as hypertension, edema, and hypokalemia, thereby making the extract safer for long-term consumption. DGL is primarily utilized as a mucosal protective agent in the management of upper gastrointestinal disorders, including gastric and duodenal ulcers, as well as gastroesophageal reflux disease (GERD). Its mechanism of action involves stimulating the proliferation of mucus-secreting cells and increasing the production of protective prostaglandins and mucus, which enhances the integrity of the mucosal barrier against gastric acid and pepsin. It is widely available as an over-the-counter dietary supplement, often formulated as chewable tablets to facilitate mixing with saliva, which is thought to activate its therapeutic properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deglycyrrhizinated licorice.